The Pharmacogene Variation Consortium (PharmVar) is now providing star (*) allele
nomenclature for the highly polymorphic human SLCO1B1 gene encoding the organic anion …

Cytochrome P450 3A (CYP3A) subfamily enzymes are involved in the metabolism of 40% of
drugs in clinical use. Twin studies have indicated that 66% of the variability in CYP3A4 …

Patients with both myasthenia gravis (MG) and SARS-CoV-2 infection face treatment
challenges due to potential drug interactions. One common immunosuppressant for MG …

Concomitant administration of multiple drugs frequently causes severe pharmacokinetic or
pharmacodynamic drug–drug interactions (DDIs) resulting in the possibility of enhanced …

Innovative pharmacogenomic approaches (genetic variation related to medication
response) are needed to reduce disease and disparities in Indigenous communities. We …

The mTOR inhibitor sirolimus is prescribed to treat children with varying diseases, ranging
from vascular anomalies to sporadic lymphangioleiomyomatosis to transplantation (solid …

Pharmacogenetic testing for CYP3A4 is increasingly provided by clinical and research
laboratories; however, only a limited number of quality control and reference materials are …

The gradual evolution of pharmacogenomics has shed light on the genetic basis for inter-
individual drug response variations across diverse populations. This study aimed to identify …

Multiple myeloma (MM) is a hematological neoplasm for which different chemotherapy
treatments are used with several drugs in combination. One of the most frequently used …

Introduction: Next-generation sequencing (NGS) technologies have been widely used in
clinical genomic testing for drug response phenotypes. However, the inherent limitations of …